<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328950</url>
  </required_header>
  <id_info>
    <org_study_id>FA5Bucy-SCT-01</org_study_id>
    <nct_id>NCT02328950</nct_id>
  </id_info>
  <brief_title>A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome</brief_title>
  <official_title>A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 5 day course of fludarabine and cytarabine (FA) will be administered followed by full
      intensity conditioning regimen (Bucy) in the setting of allogeneic stem cell transplantation
      (SCT). The purpose of this study is to explore the antileukemic, immunosuppressive effects
      and safety of FA as the backbone of a conditioning regiment for the treatment of patients
      with high-risk, recurrent or refractory acute Leukemia and advanced myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate at one year after allo-SCT</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Even free survival</measure>
    <time_frame>two year</time_frame>
    <description>Overall Survival
Leukemia Free Survival
Graft Versus Host Disease
Regimen related toxicity</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide</intervention_name>
    <description>Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with high-risk, recurrent or refractory acute leukemia and advanced
        myelodysplastic syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Aged between 0-65 years

          -  Patients suffering from either refractory de novo AML/ALL or relapsed AML/ALL or
             patients with very high risk AML/ALL in CR1

          -  Patients with advanced MDS

          -  Cardiac: Left ventricular ejection fraction ≥ 50%

          -  Adequate renal and hepatic function

          -  Performance status: Karnofsky ≥ 70%

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Current participation in another clinical trial

          -  Contra-indication to one of the drug of the regimen

          -  Any other severe concurrent disease, or have a history of serious organ dysfunction or
             disease involving the heart, kidney, liver or other organ system that may place the
             patient at undue risk to undergo the agents included in the conditioning regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Yang, Prof.</last_name>
    <phone>+86-591-83357896</phone>
    <phone_ext>8041</phone_ext>
    <email>yang.hopeting@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianda Hu, Prof.</last_name>
    <phone>+86-591-83357896</phone>
    <phone_ext>8041</phone_ext>
    <email>jdhu@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Union Hospital,Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Yang, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>yang.hopeting@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianda Hu, Prof.</last_name>
      <phone>+86-591-83357896</phone>
      <phone_ext>8041</phone_ext>
      <email>jdhu@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jianda Hu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Yang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Ting YANG</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

